Brief: Athira Pharma Announces Topline Results From Phase 2/3 Lift-Ad Clinical Trial

LeonaBio

03/09/2024 21:34

Sept 3 (Reuters) - Athira Pharma Inc  ATHA.O :
    * ATHIRA PHARMA ANNOUNCES TOPLINE RESULTS FROM PHASE 2/3
LIFT-AD
CLINICAL TRIAL OF FOSGONIMETON FOR MILD-TO-MODERATE ALZHEIMER’S
DISEASE
    * ATHIRA PHARMA INC - LIFT-AD TRIAL DID NOT MEET PRIMARY
ENDPOINT
OF GST AND KEY SECONDARY ENDPOINTS OF COGNITION (ADAS-COG11) AND
FUNCTION (ADCS-ADL23)
    * ATHIRA PHARMA INC - LIFT-AD TRIAL DOES NOT MEET PRIMARY
ENDPOINT
    * ATHIRA PHARMA INC: CONTINUES TO EVALUATE ATH-1105
    * ATHIRA PHARMA INC:  EXPECTS ATH-1105 TRIAL COMPLETION BY
YEAR-END 2024, WITH A GOAL TO BE IN ALS PATIENTS IN 2025

Source text for Eikon:  ID:nGNX5vdLQ4 
Further company coverage:  ATHA.O 

 ((Reuters.Briefs@thomsonreuters.com;))